In uterine endometrioid carcinomas, we identified ESR1 activating mutations in two patients at amino acid residue 537 resulting in a mutation hotspot commonly seen in patients with breast cancer who have become resistant to estrogen-targeted therapies. This evidence concerns the gene ESR1 and endometrial endometrioid adenocarcinoma.